ELI LILLY & Co is a large pharmaceutical company with heavy exposure to GLP-1 and obesity care and a market capitalization of $1.1738 trillion. The business has moved from mid-single-digit quarterly revenue levels into multibillion-dollar quarterly results over the past three years, placing the company at the center of the GLP-1 growth theme.
Revenue has climbed from $9,498,600,000 in CY2023Q3 to $22,974,000,000 in CY2026Q2, with repeated double‑digit year‑over‑year gains: recent quarters posted YoY increases of 55.5% (CY2026Q1), 47.7% (CY2026Q2) and 53.9% (CY2025Q3). Earnings per share moved from a loss of $0.06 in CY2023Q3 to $7.94 in CY2026Q2, with large EPS gains in several quarters. The company’s revenue and EPS growth have been strong across these quarters, though the reported measures indicate that growth rates are not currently accelerating.
The current case is straightforward: large-scale GLP-1 and obesity-care sales have driven a step-change in top-line and bottom-line results, and the shares exhibit leadership versus the broader market. That combination makes the stock a direct exposure to continued adoption and commercialization of GLP-1 therapies, while the pace of future upside will depend on competition, pricing and payer access as growth moves from steep expansion toward a steadier phase.
Why now
The setup is timely because the shares sit near a 52-week high (about 2.6% below it) while the market trend is a confirmed uptrend; technical measures show the stock outperforming the S&P (excess return +55.5% over 12 months) and the company filed recent quarterly disclosures (10-Q and several 8-Ks in August 2026), leaving the story in front of investors as quarterly results and execution drive near-term sentiment.
The setup
Price closed at $1,246.93 on 2026-08-24, above the 50-day average of $1,181.30 and the 200-day average of $1,054.68, placing the stock in an established uptrend (Weinstein Stage 2) with an RSI of 57.8 and a 50-day up/down volume ratio of 1.16; relative strength versus the S&P is strong (+14.7% excess return over 3 months, +55.5% over 12 months) and seven trend checks are passing, so the technical picture favors continuation while leaving room for near-term consolidation.
Revenue trajectory
Quarterly revenue with year-over-year growth. Solid bars are actuals from SEC EDGAR filings (XBRL); dashed bars are analyst consensus via Yahoo Finance (28 analysts).Earnings trajectory
Solid bars are quarterly GAAP diluted EPS from SEC EDGAR filings. Dashed bars are analyst consensus, which is typically adjusted (non-GAAP). The two are measured differently, so a step between the last actual and the first estimate usually reflects that change in basis rather than a change in the business.Analyst full-year EPS consensus (typically adjusted): FY'26E $36.71 (+52%) · FY'27E $47.23 (+29%) — 28 analysts
Risks
Competition and pricing pressure in the GLP-1 market are the primary risk, with large rivals able to take share or force price concessions; regulatory and payer decisions on coverage could meaningfully affect demand and revenue. Separately, growth shows signs of moving from rapid expansion toward a steadier phase — revenue and EPS are not accelerating — and the stock trades near all-time highs, creating valuation and pullback risk if execution or market conditions slip.
Framework fit
CANSLIM
5/7- CCurrent quarterly GAAP EPS growth ≥ 25%+26%✓
- AAnnual GAAP EPS growth ≥ 25%insufficient data—
- NNew highs — within 15% of 52-week high-2.61%✓
- SSupply/demand — up-day volume leads1.16x✓
- LLeader — outperforming the S&P 500+6% 6m✓
- IInstitutional sponsorship——
- MMarket in a confirmed uptrendConfirmed uptrend✓
Minervini Trend Template
7/7Stage 2 confirmation checklist: price versus rising long-term moving averages and the 52-week range.
Weinstein Stage
Established uptrend: price above a rising 200-day line.